Peer-reviewed article
Preparing for Future Group B Streptococcus Vaccines: Perspectives of Pregnant Women in Australia.
Prabha H Andraweera, Emma Jeffs, Bing Wang, Helen S Marshall ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study explored how pregnant women in Australia view a future vaccine against Group B Streptococcus (GBS), a bacterium that can harm newborns. Researchers interviewed 31 pregnant women about their knowledge of GBS, current screening practices, and acceptance of a new vaccine. Most women preferred vaccination over the current antibiotic treatment, but had concerns about vaccine safety and wanted clear, flexible information from healthcare providers they trusted.
Key points
- Protecting their baby's health was the main reason women would accept GBS vaccination
- Most participants preferred maternal vaccination over current antibiotic prophylaxis strategies
- Women expressed concerns about vaccine safety and had significant knowledge gaps about GBS
- Participants wanted vaccination to be accessible and flexible in how it was delivered
- Women preferred receiving information from trusted healthcare providers through multiple communication channels
Limitations
This study included a highly educated sample (87% with tertiary education) and over half worked in health sectors, which may not represent the views of all pregnant women. The research was conducted before the vaccine was approved, so actual uptake decisions may differ from stated intentions.
Abstract
BACKGROUND: Vaccines for Group B Streptococcus (GBS) intended for pregnant women are currently in advanced stages of clinical trials. Conducting preparatory research now can help identify factors influencing GBS vaccine acceptance and potential challenges to future implementation. METHODS: This qualitative study recruited participants nationally through social media and antenatal clinics of a maternity hospital in South Australia between December 2024 and August 2025. Eligible participants were pregnant women aged ≥18 years residing in Australia. Online interviews and focus group discussions (FGDs) were held to explore pregnant women's knowledge and perceptions of GBS, experiences with current screening and management strategies, and views on future maternal GBS vaccination. Twenty-five women participated in FGDs and six in individual interviews; FGD group sizes ranged from two to five participants. Data were analysed using inductive content analysis. RESULTS: A total of 31 pregnant women participated, aged 19-43 years. Most participants (51.6%) were from South Australia, 87.1% had tertiary education, and 51.6% were employed in the health sector. Five themes were identified: (1) infant wellbeing is the dominant driver of vaccine acceptance, (2) maternal vaccination is preferred over current antibiotic prophylaxis, (3) perceived uncertainty about vaccine safety and knowledge gaps fuel caution, (4) accessible and flexible vaccination delivery models are desired, and (5) multimodal, woman-centred communication delivered through trusted healthcare providers is required. CONCLUSIONS: Findings highlight the importance of addressing knowledge and safety concerns and incorporating accessible, flexible and woman-centred approaches into the planning of future maternal GBS vaccination programmes.